Stem Cell Therapy Using Bone Marrow-Derived Mononuclear Cells in Treatment of Lower Limb Lymphedema: A Randomized Controlled Clinical Trial

Ismail, Ahmed M.; Abdou, Said; Abdelnaby, Amira Y; Hamdy, Mennat Allah; Elsaka, Ayman Mohamed; Gawaly, Amr M.

doi:10.1089/lrb.2017.0027

Cited by 19 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure 4 In a similar recent study, Ismail et al discovered that BDRCs also increased the efficacy of CDT in primary lower limb lymphedema. 16 However, this study too may have been subject to performance bias, namely, a systematic difference in exposure to compression therapy between the BDRC and CDT groups. Compression therapy is a known confounder for volume reduction in lymphedema, as significant volume reduction can be credited to this treatment alone.…”

Section: Discussionmentioning

confidence: 95%

“…4 Overall, we did not find the adipose-derived treatment to decrease the volume of lymphedema, whereas other studies have found considerable reduction. [14][15][16] However, these studies all used bone marrow-derived regenerative cells (BDRCs); these cells also stem from the mesenchymal progenitor line and have regenerative properties comparable to adipose-derived cells. [17][18][19] Maldona et al showed that BDRC treatment without compression sleeve was as effective as compression sleeve alone in decreasing BCRL volume.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adipose-derived regenerative cells and lipotransfer in alleviating breast cancer-related lymphedema: An open-label phase I trial with 4 years of follow-up

Jørgensen

Toyserkani

Jensen

et al. 2021

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Patients with breast cancer-related lymphedema (BCRL) have reduced quality of life and arm function. Current treatments are palliative, and treatments improving lymphedema are lacking. Preclinical studies have suggested that adipose-derived regenerative cells (ADRCs) can alleviate lymphedema. We, therefore, aimed to assess whether ADRCs can alleviate lymphedema in clinical reality with long-term follow-up. We treated 10 patients with BCRL using ADRCs and a scar-releasing lipotransfer to the axillary region, and all patients were followed 1, 3, 6, 12, and 48 months after treatment. The primary endpoint was change in arm volume. Secondary endpoints were safety, change in lymphedema symptoms, quality of life, lymphedema-associated cellulitis, and conservative treatment use. There was no significant decrease in BCRL volume after treatment. However, self-reported upper extremity disability and arm heaviness and tension improved. Six patients reduced their use of conservative BCRL treatment. Five patients felt that their BCRL had improved substantially, and four of these would redo the treatment. We did not observe any cases of locoregional breast cancer recurrence. In this phase I study with 4 years of follow-up, axillary delivered ADRCs and lipotransfer were safe and feasible and improved BCRL symptoms and upper extremity function. Randomized controlled trials are needed to confirm the results of this study.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Adipose-derived regenerative cells and lipotransfer in alleviating breast cancer-related lymphedema: An open-label phase I trial with 4 years of follow-up

Jørgensen

Toyserkani

Jensen

et al. 2021

Stem Cells Translational Medicine

View full text Add to dashboard Cite

show abstract

“…Several studies have reported the outcomes of cell-based therapy on patients with lymphedema and the results are promising (Table 1). [106][107][108][109][110][111] Maldonado et al randomized 20 patients with breast cancer-related lymphedema (BCRL) to receive intramuscular BMSC injection in the affected arm (n = 10) or traditional compression therapy (n = 10). At a follow-up of 12 weeks, both groups showed a similar reduction in lymphedema volume.…”

Section: Clinical Studiesmentioning

confidence: 99%

Tissue Engineering Strategies for Cancer-Related Lymphedema

Asaad

Hanson

2021

Tissue Engineering Part A

View full text Add to dashboard Cite

Tissue engineering has witnessed remarkable advancement in various fields of medicine and has the potential of revolutionizing the management of lymphedema. Combining approaches of biotechnology with the evolving understanding of lymphangiogenesis may offer promising treatment modalities for patients suffering from lymphedema. The strategies to lymphatic vessels tissue engineer can be grouped into four main categories: Delivery of chemokines, cytokines, and other growth factors to induce lymphangiogenesis; cell-based approach using lymphatic endothelial cells or stem-cells; scaffold-based tissue engineering; or a combination of these. This review will summarize the current approach to cancer-related lymphedema and advances in lymphatic tissue engineering strategies and the challenges facing the regeneration of lymphatic vasculature, particularly in an oncologic setting.

show abstract

“…Other stem cells may also play a role in the treatment of lymphedema, but little research has been done. Mononuclear cells (MNCs) can potentially alleviate lymphedema through stimulation of lymph‐angiogenesis 60 . Spitalieri et al .…”

Section: Therapeutic Effect Of Stem Cell In Lymphedemamentioning

confidence: 99%

“…Mononuclear cells (MNCs) can potentially alleviate lymphedema through stimulation of lymph-angiogenesis. 60 Spitalieri et al explored generation of human-induced pluripotent stem cells (hiPSCs) derived from autologous extra-embryonic fetal tissues. This innovative personalized regenerative technology can transform cells into embryonic stem-like cells.…”

Section: Stem Cell Therapy For Lymphedemamentioning

confidence: 99%

Therapeutic Potential of Mesenchymal Stem Cells for Postmastectomy Lymphedema: A Literature Review

Chen

Sinelnikov

Reshetov

et al. 2020

Clinical Translational Sci

View full text Add to dashboard Cite

Upper limb lymphedema is one of the most common complications after breast cancer surgery and radiotherapy. Despite various physical therapy and surgical options available, the impaired lymph fluid drainage may be progressive due to lymphatic vascular insufficiency making treatment more difficulty. Stem cell therapy provides a promising alternative in the treatment of various chronic diseases. The wide applicability of cell therapy has been reviewed throughout literature. This review provides an overview of recent progress in the therapeutic effect of adult stem cells for primary and secondary lymphedema after breast surgery in preclinical studies and clinical cases. We start with a brief introduction about the pathophysiological mechanisms of postmastectomy lymphedema. Regarding existing treatments, we systematically summarize the benefits and limitations of recent progress. Because of their multidirectional differentiation potential and growth factor secretion, stem cell therapy shows promising results in the management of light to severe lymphedema. Increasing evidences have demonstrated a noticeable reduction in postmastectomy lymphedema and increased lymph‐angiogenesis after specific stem cell therapy. Current data suggests that stem cell therapy in lymphedema treatment provides reversal of pathological reorganization associated with lymphedema progression. Finally, we propose potential strategies for overcoming the challenges in the development of multipotent progenitor cells for the treatment and prevention of lymphedema in clinical practice.

show abstract

Stem Cell Therapy Using Bone Marrow-Derived Mononuclear Cells in Treatment of Lower Limb Lymphedema: A Randomized Controlled Clinical Trial

Abstract: Stem cell therapy can achieve improvement in limb circumference as well as pain relief and improvement in walking ability in patients with chronic lymphedema compared with those in control group.

Cited by 19 publications

References 21 publications

Adipose-derived regenerative cells and lipotransfer in alleviating breast cancer-related lymphedema: An open-label phase I trial with 4 years of follow-up

Adipose-derived regenerative cells and lipotransfer in alleviating breast cancer-related lymphedema: An open-label phase I trial with 4 years of follow-up

Tissue Engineering Strategies for Cancer-Related Lymphedema

Therapeutic Potential of Mesenchymal Stem Cells for Postmastectomy Lymphedema: A Literature Review

Contact Info

Product

Resources

About